MAM
LGND icon

Martingale Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

Martingale Asset Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.55M Buy
17,762
+2,440
+16% +$483K 0.09% 219
2025
Q4 		$2.9M Sell
15,322
-3,150
-17% -$605K 0.07% 244
2025
Q3 		$3.27M Sell
18,472
-1,681
-8% -$250K 0.08% 206
2025
Q2 		$2.29M Buy
20,153
+1,101
+6% +$118K 0.06% 277
2025
Q1 		$2M Buy
19,052
+960
+5% +$109K 0.05% 300
2024
Q4 		$1.94M Buy
18,092
+270
+2% +$30.5K 0.05% 318
2024
Q3 		$1.78M Sell
17,822
-2,200
-11% -$221K 0.04% 341
2024
Q2 		$1.69M Sell
20,022
-11,757
-37% -$936K 0.04% 341
2024
Q1 		$2.32M Sell
31,779
-180
-0.6% -$13.3K 0.05% 265
2023
Q4 		$2.28M Sell
31,959
-165
-0.5% -$9.74K 0.05% 258
2023
Q3 		$1.92M Buy
32,124
+3,853
+14% +$254K 0.04% 274
2023
Q2 		$2.04M Buy
28,271
+16,380
+138% +$1.23M 0.04% 272
2023
Q1 		$875K Buy
+11,891
New +$845K 0.02% 477
2019
Q2 		– Sell
-7,055
Closed -$554K – 1039
2019
Q1 		$554K Sell
7,055
-18,596
-72% -$1.41M 0.01% 875
2018
Q4 		$2.17M Sell
25,651
-483
-2% -$51.5K 0.03% 514
2018
Q3 		$4.48M Buy
26,134
+2
+0% +$302 0.05% 338
2018
Q2 		$3.38M Hold
26,132
– – 0.04% 412
2018
Q1 		$2.69M Sell
26,132
-321
-1% -$31.7K 0.03% 452
2017
Q4 		$2.26M Buy
26,453
+14,269
+117% +$1.24M 0.03% 503
2017
Q3 		$1.03M Buy
+12,184
New +$965K 0.01% 717
2016
Q4 		– Sell
-8,336
Closed -$531K – 989
2016
Q3 		$531K Buy
+8,336
New +$612K 0.01% 800

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Martingale Asset Management's LGND Position: Q1 2026 in Review

Martingale Asset Management increased its Ligand Pharmaceuticals (LGND) stake by 16% in Q1 2026, buying an estimated $483K and bringing the position to 17,762 shares worth $3.55M. The position accounts for 0.09% of the portfolio, ranked #219.

Martingale Asset Management first reported a position in LGND in Q3 2016 and has held it in 21 quarters since. The position peaked at $4.48M in Q3 2018. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Martingale Asset Management held 17,762 shares of Ligand Pharmaceuticals worth $3.55M as of Q1 2026.
  • Martingale Asset Management bought 2,440 Ligand Pharmaceuticals shares in Q1 2026, an estimated $483K.
  • Ligand Pharmaceuticals made up 0.09% of Martingale Asset Management's portfolio in Q1 2026, its #219 holding.
  • Martingale Asset Management first reported a position in Ligand Pharmaceuticals in Q3 2016 and has held it in 21 quarters since.
  • Martingale Asset Management's Ligand Pharmaceuticals position peaked at $4.48M in Q3 2018.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Martingale Asset Management's 13F filing for Q1 2026, filed 13 May 2026.